(WILMINGTON, Del. -- August 23, 2021)
Today, the U.S. Food and Drug Administration announced full approval of the Pfizer-BioNTech COVID-19 Vaccine, which will be marketed as Comirnaty (koe-mir’-na-tee), for the prevention of COVID-19 disease in individuals 16 years of age and older.
The vaccine continues to be available under emergency use authorization (EUA), including for individuals 12 through 15 years of age and for the administration of a third dose in certain immunocompromised individuals.
Read the full announcement from the FDA here.
This is another milestone in our battle against COVID-19 and our fight to end this pandemic.
We’ve known for months now that the COVID-19 vaccines are safe and effective, as billions of people worldwide have been fully vaccinated, and serious side effects have been extremely rare. This final step in FDA approval for the first of the COVID-19 vaccines is a symbol of what we can achieve together and addresses the concerns of those who were reluctant to get vaccinated while it was under EUA. With the current surge from the delta variant and the unvaccinated, the vaccine represents hope.
No one is more hopeful for the end of this pandemic than our caregivers, who have been working to save lives and protect our community. This vaccine approval is another sign that this marathon could one day be over—the finish line is coming into focus.
To get there, and to win this marathon, we must work together. We must get enough people vaccinated—everywhere—until the virus has few opportunities left to spread. That is the way out of the pandemic.
We call on everyone who is not yet vaccinated to take this important step today—to protect yourself, your family and the people around you. Amid the challenges and hardships, the grief and suffering of the past year and a half, we have made incredible progress. In the face of the most significant global health crisis experienced in generations, humanity is gaining the upper hand—and we will triumph.
Janice E. Nevin, M.D., MPH
President & CEO
Need an expert source?
Our Experts, ChristianaCare's expert database, can help you find the right source for your next news story.
Request an interview ➜
Headquartered in Wilmington, Delaware, ChristianaCare is one of the country’s most dynamic health care organizations, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,430 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women’s health. It also includes the pioneering Gene Editing Institute.
ChristianaCare is nationally recognized as a great place to work, rated by Forbes as the 2nd best health system for diversity and inclusion, and the 29th best health system to work for in the United States, and by IDG Computerworld as one of the nation’s Best Places to Work in IT. ChristianaCare is rated by Healthgrades as one of America’s 50 Best Hospitals and continually ranked among the nation’s best by U.S. News & World Report, Newsweek and other national quality ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.